This bill would add pharmacist services to Medicare Part B coverage for beneficiaries, specifically covering pharmacist-led testing and treatment for illnesses like flu, COVID-19, or strep throat during public health emergencies. It defines covered services as those performed under state law, often requiring collaboration with a physician, and sets payment at 80% of the lesser of the actual charge or 85% of physician payment rates. Pharmacists would be prohibited from balance billing for these services, ensuring Medicare beneficiaries pay only their standard copayment. The changes would take effect January 1, 2026.
This bill makes payments to clinical trial participants tax-free and ensures those payments won't count toward income limits for federal programs like Medicaid or food assistance. It covers both compensation for participation and reimbursement of reasonable expenses (like travel) related to approved clinical trials for life-threatening conditions. The exclusion applies to payments made after December 31, 2025, and is defined in the bill using existing IRS and Public Health Service Act terms.
HR 2960 extends funding for a program that provides payments to children's hospitals operating graduate medical education (GME) programs. The bill amends the Public Health Service Act to change the program's expiration date from 2023 to 2030 across multiple sections. This directly affects eligible children's hospitals by ensuring continued financial support for training physicians in pediatric care. The key change is simply extending the program's authorization period without altering the payment structure or eligibility rules.
This bill establishes a federal grant program to fund mobile vaccination units in states, directly affecting state health departments and local communities. It authorizes the Secretary to award grants for states to establish or expand mobile units that provide recommended childhood, adolescent, and adult immunizations, covering vehicle acquisition, equipment, and vaccine costs. States must submit applications and use funds solely for these mobile units, with the Secretary required to report on the program's effectiveness to Congress by September 2027. The program is funded for fiscal year 2027 with no specified budget amount.
This bill requires the Health and Human Services (HHS) Secretary to update all HHS grant program regulations and guidance related to opioid misuse to include *all* FDA-approved opioid overdose reversal drugs - not just naloxone. It specifically targets two key grant programs: the State Opioid Response Grants (under the 21st Century Cures Act) and the Tribal Opioid Response Grants, plus the Public Health Service Act's grant program for regional/national substance use disorder prevention. HHS must update existing references within one year of the bill's enactment to ensure grants cover any approved reversal drug. This directly affects states, tribes, and community organizations receiving these federal grants for opioid response programs.
The PASTEUR Act of 2026 creates a new government contracting program to incentivize development of new antimicrobial drugs for treating drug-resistant infections. The Health and Human Services Secretary would award contracts to pharmaceutical sponsors meeting specific criteria on clinical benefits, innovation, and public health impact, with annual payments ranging from $75 million to $300 million (adjusted for inflation). Contract requirements include ensuring drug availability, tracking resistance data, promoting appropriate use, and maintaining supply chains. The bill also establishes antimicrobial stewardship programs for hospitals and outpatient facilities and improves surveillance of antimicrobial use and resistance. This legislation aims to address antibiotic resistance by creating financial incentives for new treatments and improving how antimicrobials are used and monitored.
S 786, the Public Health Funding Restoration Act, restores annual funding for the Prevention and Public Health Fund under the Affordable Care Act to $2 billion starting in fiscal year 2026. This bill directly affects federal health programs at the Department of Health and Human Services (HHS), as well as state, local, tribal, and territorial health departments. The key provision amends the Affordable Care Act to set this specific funding level, reversing prior cuts and ensuring resources for evidence-based prevention programs like immunizations, tobacco cessation, chronic disease prevention, and pandemic preparedness. The restored funding aims to support community health initiatives that have demonstrated cost savings - such as $16.50 saved per $1 spent on childhood vaccines - while strengthening public health infrastructure nationwide.
This bill creates a new grant program to help schools access naloxone for opioid overdose emergencies. It directly affects public and private elementary and secondary schools by requiring them to certify they have trained staff (like nurses or designated personnel), maintain accessible naloxone supplies, and have a plan for trained staff on-site during school hours. Schools must also confirm their state provides adequate legal protection for staff who administer naloxone. The grants, funded through the Public Health Service Act, support these requirements to enable immediate emergency treatment of opioid overdoses in school settings.
HR 593 exempts certain health profession loan repayments and scholarship payments from federal income tax. It applies to individuals participating in Public Health Service Act programs (like sections 338B, 846, and 338K) and state programs designed to increase healthcare access in underserved areas. The bill also includes scholarships under the Native Hawaiian Health Care Improvement Act in this tax exclusion. These changes take effect for payments received after the bill's enactment date.
This document appears to be a comprehensive legislative bill, likely titled the "Pandemic and All-Hazards Preparedness and Response Act" or a similar public health bill. It contains numerous sections (numbered 201-625) with detailed provisions covering:
1. **Public Health Emergency Preparedness** - Sections 611-617 focus on strengthening state/local readiness, hospital preparedness, wastewater surveillance, and medical stockpiles.
2. **Opioid Crisis Response** - Sections 521-522, 531-539 address opioid prevention, treatment, recovery, and workforce development.
3. **Mental Health and Substance Use Disorder** - Sections 531-539 include grants for treatment, peer support, and workforce development.
4. **Suicide Prevention** - Section 518 focuses on protecting the National Suicide Prevention Lifeline from cybersecurity threats.
5. **Public Health Infrastructure** - Sections 621-625 cover medical countermeasures, antimicrobial resistance, and strategic stockpile management.
6. **Technical Corrections** - Sections 551-554 include technical amendments to controlled substances laws.
The bill contains numerous funding authorizations (e.g., $735 million for Public Health Emergency Preparedness for fiscal years 2025-2026), reauthorizations of existing programs, and new initiatives aimed at strengthening the U.S. public health response system to both infectious disease threats and the opioid crisis.
Without a specific question about this document, I've provided a general overview of its content and scope. If you have a specific question about any section or provision, please let me know.
